Table 1.
Baseline Characteristics of Study Participants with and without Bacterial Pneumonia Events
| IL-2 with event |
Control with event |
All patients without event |
|
|---|---|---|---|
| Demographics | |||
| Age in Years (Median,IQR) | 43 (37, 50) | 41 (37, 49) | 40 (34, 46) |
| Female Gender (%) | 16.1 | 12.8 | 18.8 |
| Race (%) | |||
| Asian | 1.1 | 2.3 | 11.2 |
| Black | 10.8 | 5.8 | 9.2 |
| White | 83.9 | 86.0 | 74.9 |
| Other/unknown | 4.3 | 5.8 | 4.8 |
| Injection drug use (%) | 16.1 | 19.8 | 10.2 |
| CD4+ count (cells/μL)(median,IQR) | 420 (356, 556) | 425 (364, 634) | 458 (373, 584) |
| CD4+ Nadir (cells/ μL)(median,IQR) | 175 (55, 270) | 169 (93, 273) | 198 (91, 310) |
| HIV RNA ≤ 500 copies (%) | 66.7 | 74.4 | 80.1 |
| Medical History | |||
| AIDS diagnosis (%) | 34.4 | 33.7 | 25.5 |
| History of recurrent BP (%) | 15.1 | 3.5 | 5.9 |
| Hepatitis B (% HBsAg pos.) | 2.4 | 6.3 | 6.5 |
| Hepatitis C (% antibody pos.) | 22.9 | 23.1 | 14.9 |
| ART History | |||
| Years since 1st ART (median, IQR) | 5.1 (2.1, 7.9) | 4.9 (2.9, 7.8) | 4.2 (2.1, 6.4) |
| PcP prophylaxis (%) | 7.5 | 4.7 | 6.2 |
a)
More than one can be checked.